Neuriva
Allegations: Falsely marketing that products have been “clinically tested” to provide various brain health benefits
Ozuzu et al. v. Kenvue Inc., McNeil Consumer Healthcare, and Reckitt Benckiser, LLC
23-cv-7395, E.D.N.Y.
(Oct. 2023)
Tylenol Cold & Flu Severe, Mucinex Sinus Max, and other phenylephrine products
Falsely marketing that medicines treat nasal congestion when the active ingredient (phenylephrine) is not an effective decongestant
Pending
Allegations: Falsely marketing that products have been “clinically tested” to provide various brain health benefits
Allegations: Falsely marketing products as safe, healthy, nutritious, and committed to reducing their environmental impact
Allegations: Deceptively marketing products as “nutritionally appropriate” for children between nine and eighteen months
Allegations: Falsely marketing products as safe when they are dangerous for premature infants
Allegations: Failing to disclose that products contain PFAS
Allegations: Misleadingly marketing products as safe when they contained, or were at risk of containing, the carcinogen benzene
Allegations: Failing to disclose that products contain toxic heavy metals
Allegations: Misleadingly representing that products were safe and tested by dermatologists when they contained, or were at risk of containing, the carcinogen benzene
Allegations: Misleadingly marketing that the detergent “kills 99.9% of bacteria”
Allegations: Deceptively marketing that detergents bring color back to clothing
Allegations: Falsely marketing that phenylephrine products treat nasal congestion
Allegations: Falsely marketing that medicines treat nasal congestion
Allegations: Falsely marketing that medicines are decongestants
Allegations: Falsely marketing that products provide relief from congestion, sinus pressure and other symptoms
Allegations: Falsely marketing the products treat nasal congestion
Allegations: Falsely marketing that products contain sandalwood essential oil
Allegations: Falsely marketing that medicines treat nasal congestion
Allegations: Falsely marketing medicines as decongestants
Allegations: Falsely marketing that products treat nasal congestion
Allegations: Falsely marketing that medicines treat congestion
Allegations: Falsely marketing medicines as nasal decongestants
Allegations: Falsely marketing that medicines treat congestion
Allegations: Falsely marketing that medicines relieve nasal congestion and sinus pressure
Allegations: Falsely marketing medicines as nasal decongestants
Allegations: Falsely marketing that phenylephrine products treat congestion and other cold and flu symptoms
Allegations: Falsely marketing medicines as decongestants
Allegations: Falsely marketing medicines as decongestants
Allegations: Falsely marketing that medicines treat nasal congestion
Allegations: Falsely marketing that medicines treat congestion
Allegations: Falsely marketing that medicines treat congestion and other sinus issues
Allegations: Falsely marketing Neuriva supplements as “clinically proven” to improve “brain performance” when the company has no scientific or clinical proof that the supplements or ingredients in them provide the…
Allegations: Misleadingly marketing infant formulas as “Milk-based” when the primary ingredient is a form of sugar
Allegations: Products do not contain enough powder to make the advertised number of bottles
Allegations: Misleadingly marketing certain products as being for children and others as being for adults when the products contain the same amounts of the same ingredients
Allegations: Falsely advertising that Move Free provides joint health benefits when the ingredients in the supplement do not provide such benefits
An industry self-regulatory board looks to clean up Lysol’s claims.
Readers have told us to look into these MLMs.
TINA.org Joins with AARP in Objecting to Move Free Class-Action Settlement MADISON, Conn., March 12, 2015 — More than 46 million people suffer from arthritis, many of them elderly, and…
Consumers report adverse reactions.
Class-action settlement over supplement sold by Walmart, Walgreens and Supervalu provides little relief to consumers.